Stockscreener 앱 받기
1.01
3.80%
0.037
전일 마감가:
$0.973
열려 있는:
$1
하루 거래량:
1.90M
Relative Volume:
2.49
시가총액:
$108.68M
수익:
-
순이익/손실:
$-20.31M
주가수익비율:
-3.8185
EPS:
-0.2645
순현금흐름:
$-21.07M
1주 성능:
+4.37%
1개월 성능:
-2.88%
6개월 성능:
-19.20%
1년 성능:
+20.45%
1일 변동 폭
$1.00
$1.08
1주일 범위
$0.92
$1.08
52주 변동 폭
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
ONCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.01 | 104.70M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-13 | 개시 | Lake Street | Buy |
| 2022-10-06 | 개시 | Maxim Group | Buy |
| 2021-02-17 | 개시 | H.C. Wainwright | Buy |
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Stocks In Play - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Announces Results of Special Meeting of Shareholders - marketscreener.com
Oncolytics Biotech Shareholders Approve Redomiciliation to Nevada and New Incentive Plan - TipRanks
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders - The Manila Times
Oncolytics Biotech Inc. Announces Approval of Shareholder Resolutions at Special Meeting - Quiver Quantitative
ONCY: All resolutions, including corporate moves and the 2026 Incentive Plan, were approved by shareholders - TradingView — Track All Markets
Oncolytics Biotech Inc Announces Key Executive Appointments - TradingView — Track All Markets
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - The Globe and Mail
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics - Sahm
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Oncolytics Biotech Inc. Appoints John McAdory as Executive Vice President of Strategy and Operations - marketscreener.com
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era - The Manila Times
Oncolytics Biotech Bolsters Late-Stage Cancer Push With New Strategy and Biostatistics Leaders - TipRanks
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush - The Globe and Mail
THE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke Points - GlobeNewswire
Oncolytics Biotech Inc. Appoints New Executive Team Members to Enhance Strategic Operations and Clinical Development - Quiver Quantitative
Where are the Opportunities in (ONC) (ONC:CA) - Stock Traders Daily
Stop Loss: How Oncolytics Biotech Inc stock reacts to Fed rate cutsEarnings Risk Report & Free Reliable Trade Execution Plans - Bộ Nội Vụ
Oncolytics Biotech Advances Immunotherapy for Accelerated Approval in Oncology - Intellectia AI
Oncolytics Biotech Data Signal Registration Path for Pelareorep Combo in Third-Line Anal Cancer - TipRanks
Pelareorep-atezolizumab shows promising results in anal cancer - Investing.com
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - The Malaysian Reserve
Stocks in play: Oncolytics Biotech Inc - Barchart.com
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff - GlobeNewswire
Oncolytics (ONCY) Presents Promising Data for SCAC Treatment - GuruFocus
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer - The Manila Times
Oncolytics Biotech Reports Promising Clinical Data for Pelareorep-Atezolizumab Combination in Third-Line Metastatic Anal Cancer - Quiver Quantitative
Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances - Finviz
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Oncolytics Biotech plans to shift incorporation from Canada to Nevada By Investing.com - Investing.com Nigeria
Oncolytics outlines strategic rationale for proposal to change jurisdiction - Yahoo Finance
Oncolytics Biotech plans to shift incorporation from Canada to Nevada - Investing.com Canada
10 Stocks Under $1 That Will Explode - Insider Monkey
Stocks in play: Oncolytics Biotech Inc. - Barchart.com
Oncolytics (ONCY) Plans to Shift Incorporation to Nevada for Str - GuruFocus
Oncolytics Biotech Seeks Nevada Domestication to Align with U.S. Growth Strategy - TipRanks
Oncolytics Biotech files patent application to extend pelareorep protection By Investing.com - Investing.com Nigeria
Oncolytics Biotech Inc. Proposes Change of Jurisdiction to Nevada to Enhance U.S. Focus and Strategic Growth - Quiver Quantitative
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada - Yahoo Finance
Oncolytics Biotech Inc. - Menafn
Is Oncolytics Biotech Inc. stock a contrarian buyInsider Buying & Technical Analysis for Trade Confirmation - Улправда
Is Oncolytics Biotech Inc. stock a buy for dividend growth - Улправда
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech - The Manila Times
The $537B Precision Pivot: Why Molecular Monitoring is the New Oncology Standard - The Globe and Mail
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings - PharmiWeb.com
Oncolytics Biotech Inc (ONCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):